Paris-based biotech Rivercell has raised $25m in seed funding to build an AI model that understands and predicts the behaviour of human cells. The company aims to significantly boost drug discovery efforts through its world model for human cells. The round was led by Sequoia Capital and BPI France, with participation from Acreo and other investors.
The founding team includes professionals with backgrounds at Owkin, a leading AI in healthcare company. "This investment validates our vision of using AI to accelerate biomedical research," said one of the founders. The funds will be used to expand the team and advance the development of their predictive cell model.
Source: Sifted · Summarized by HeadlinesBriefing